FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295633058> ?p ?o ?g. }

• W4295633058 endingPage "1264" @default.
• W4295633058 startingPage "1258" @default.
• W4295633058 abstract "ABSTRACT Background Focal segmental glomerular sclerosis (FSGS) is a histologic lesion rather than a specific disease entity and represents a cluster of different conditions affecting both children and adults that includes primary, secondary and genetically mediated forms. These forms can be distinguished by electron microscopy and genetic assessment and show different responsiveness to steroids and immunosuppressants. Despite some promising effects of rituximab in nephrotic syndrome in children, the results in adults with FSGS are disappointing. Our group previously explored the effectiveness of rituximab in eight adult patients with unselected forms of FSGS and achieved a consistent reduction in proteinuria in one case. Following this experience, we developed an alternative therapeutic option intended to enhance the potential of rituximab with the support of other synergic drugs. We herein report the results of this therapeutic protocol (six administrations of rituximab plus two of intravenous cyclophosphamide plus glucocorticoids) in seven prospectively enrolled patients with extensive podocyte effacement and recurrent relapses or steroid dependence. Results Patients had a median baseline serum creatinine level of 2.2 mg/dl (range 1–4.7) that decreased to 1.1 mg/dl (range 0.9–2.2) and 1.1 mg/dl (range 0.75–2.21) after 3 and 6 months, respectively, and remained unchanged at 12 months. Three of five patients with renal failure turned to normal function while the other two patients maintained a stable impairment after 18 and 52 months. The median proteinuria decreased from 6.1 g/24 h to 3.5, 3.5 and 1.9 g/24 h at 3, 6 and 12 months, respectively. Specifically, five of seven patients had a partial response at 12 months and became non-nephrotic. One of them had a complete response at 18 months and was still in complete remission at the last follow-up visit at 36 months. Proteinuria persisted unchanged in two of seven patients with a genetic-related disease. No serious late adverse events were observed. Conclusions Our results show that intensive B-cell depletion therapy is able to reverse the nephrotic syndrome of steroid-dependent or frequently relapsing adult patients with putatively idiopathic FSGS (i.e. with extensive podocyte effacement)." @default.
• W4295633058 created "2022-09-14" @default.
• W4295633058 creator A5006961959 @default.
• W4295633058 creator A5012705049 @default.
• W4295633058 creator A5017039749 @default.
• W4295633058 creator A5043758235 @default.
• W4295633058 creator A5058598522 @default.
• W4295633058 creator A5059780181 @default.
• W4295633058 creator A5062514406 @default.
• W4295633058 creator A5086035399 @default.
• W4295633058 date "2022-09-12" @default.
• W4295633058 modified "2023-10-16" @default.
• W4295633058 title "Focal segmental glomerular sclerosis can be effectively treated using an intensive B-cell depletion therapy" @default.
• W4295633058 cites W1765855 @default.
• W4295633058 cites W1979066197 @default.
• W4295633058 cites W2061859386 @default.
• W4295633058 cites W2105835861 @default.
• W4295633058 cites W2107015722 @default.
• W4295633058 cites W2124215501 @default.
• W4295633058 cites W2131980568 @default.
• W4295633058 cites W2133284524 @default.
• W4295633058 cites W2134547857 @default.
• W4295633058 cites W2141947091 @default.
• W4295633058 cites W2584442866 @default.
• W4295633058 cites W2593771998 @default.
• W4295633058 cites W2734555149 @default.
• W4295633058 cites W2966423636 @default.
• W4295633058 cites W3108919101 @default.
• W4295633058 cites W3119481005 @default.
• W4295633058 cites W3128714093 @default.
• W4295633058 cites W3162886856 @default.
• W4295633058 cites W3208894493 @default.
• W4295633058 cites W3214622032 @default.
• W4295633058 cites W4225908351 @default.
• W4295633058 doi "https://doi.org/10.1093/ckj/sfac207" @default.
• W4295633058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37529640" @default.
• W4295633058 hasPublicationYear "2022" @default.
• W4295633058 type Work @default.
• W4295633058 citedByCount "0" @default.
• W4295633058 crossrefType "journal-article" @default.
• W4295633058 hasAuthorship W4295633058A5006961959 @default.
• W4295633058 hasAuthorship W4295633058A5012705049 @default.
• W4295633058 hasAuthorship W4295633058A5017039749 @default.
• W4295633058 hasAuthorship W4295633058A5043758235 @default.
• W4295633058 hasAuthorship W4295633058A5058598522 @default.
• W4295633058 hasAuthorship W4295633058A5059780181 @default.
• W4295633058 hasAuthorship W4295633058A5062514406 @default.
• W4295633058 hasAuthorship W4295633058A5086035399 @default.
• W4295633058 hasConcept C126322002 @default.
• W4295633058 hasConcept C126894567 @default.
• W4295633058 hasConcept C159641895 @default.
• W4295633058 hasConcept C2776694085 @default.
• W4295633058 hasConcept C2776755627 @default.
• W4295633058 hasConcept C2777146197 @default.
• W4295633058 hasConcept C2777747828 @default.
• W4295633058 hasConcept C2778415529 @default.
• W4295633058 hasConcept C2778930706 @default.
• W4295633058 hasConcept C2779338263 @default.
• W4295633058 hasConcept C2779561371 @default.
• W4295633058 hasConcept C2780091579 @default.
• W4295633058 hasConcept C2780306776 @default.
• W4295633058 hasConcept C2780653079 @default.
• W4295633058 hasConcept C71924100 @default.
• W4295633058 hasConcept C90924648 @default.
• W4295633058 hasConceptScore W4295633058C126322002 @default.
• W4295633058 hasConceptScore W4295633058C126894567 @default.
• W4295633058 hasConceptScore W4295633058C159641895 @default.
• W4295633058 hasConceptScore W4295633058C2776694085 @default.
• W4295633058 hasConceptScore W4295633058C2776755627 @default.
• W4295633058 hasConceptScore W4295633058C2777146197 @default.
• W4295633058 hasConceptScore W4295633058C2777747828 @default.
• W4295633058 hasConceptScore W4295633058C2778415529 @default.
• W4295633058 hasConceptScore W4295633058C2778930706 @default.
• W4295633058 hasConceptScore W4295633058C2779338263 @default.
• W4295633058 hasConceptScore W4295633058C2779561371 @default.
• W4295633058 hasConceptScore W4295633058C2780091579 @default.
• W4295633058 hasConceptScore W4295633058C2780306776 @default.
• W4295633058 hasConceptScore W4295633058C2780653079 @default.
• W4295633058 hasConceptScore W4295633058C71924100 @default.
• W4295633058 hasConceptScore W4295633058C90924648 @default.
• W4295633058 hasIssue "8" @default.
• W4295633058 hasLocation W42956330581 @default.
• W4295633058 hasLocation W42956330582 @default.
• W4295633058 hasOpenAccess W4295633058 @default.
• W4295633058 hasPrimaryLocation W42956330581 @default.
• W4295633058 hasRelatedWork W1765855 @default.
• W4295633058 hasRelatedWork W1964669350 @default.
• W4295633058 hasRelatedWork W2033492666 @default.
• W4295633058 hasRelatedWork W2042732525 @default.
• W4295633058 hasRelatedWork W2159732018 @default.
• W4295633058 hasRelatedWork W2384094741 @default.
• W4295633058 hasRelatedWork W2571795535 @default.
• W4295633058 hasRelatedWork W2999496855 @default.
• W4295633058 hasRelatedWork W4295633058 @default.
• W4295633058 hasRelatedWork W2517178969 @default.
• W4295633058 hasVolume "16" @default.
• W4295633058 isParatext "false" @default.
• W4295633058 isRetracted "false" @default.

• next